KalVista Pharmaceuticals (KALV) Assets Average (2015 - 2025)

KalVista Pharmaceuticals' Assets Average history runs 11 years deep, the most recent figure standing at $233.1 million for Q3 2025.

• In Q3 2025, Assets Average rose 7.04% year-over-year to $233.1 million; the TTM figure through Jul 2025 stood at $233.1 million (up 7.04% YoY), while the FY2025 annual figure was $243.1 million, up 16.14% from the prior year.
• Assets Average came in at $233.1 million for Q3 2025 at KalVista Pharmaceuticals, down from $272.8 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $272.8 million in Q2 2025 to a low of $70.8 million in Q1 2021.
• A 5-year average of $194.9 million and a median of $193.1 million in 2022 frame the typical range for Assets Average.
• Across the five-year window, Assets Average plunged 34.11% in 2021 and jumped 230.99% in 2022, its largest moves.
• KalVista Pharmaceuticals' Assets Average stood at $251.5 million in 2021, then slumped by 31.37% to $172.6 million in 2022, then decreased by 13.35% to $149.5 million in 2023, then soared by 52.35% to $227.8 million in 2024, then grew by 2.33% to $233.1 million in 2025.
• According to Business Quant data, Assets Average over the past three periods registered $233.1 million, $272.8 million, and $227.8 million for Q3 2025, Q2 2025, and Q4 2024 respectively.

Peer Comparison